

Faculteit Farmaceutische, Biomedische en Diergeneeskundige Wetenschappen  
**Biomedische Wetenschappen, Universiteit Antwerpen**

Departement voor Microbiologie, Unit voor Virologie  
**Prins Leopold Instituut voor Tropische Geneeskunde**

**Development of Microbicides for the Prevention of HIV  
Transmission in an *in vitro* System of Dendritic cells  
and CD4<sup>+</sup> T cells with Emphasis on Synergistic Activity  
and Avoidance of Viral Resistance**

**Katty Terrazas - Aranda**

Thesis submitted in fulfilment of the requirements for the degree of  
Doctor of Philosophy in Biomedical Sciences

Proefschrift voorgelegd tot het behalen van de graad van  
Doctor in de Biomedische Wetenschappen

**Promotor:** Prof. Dr. Guido Vanham



**Antwerpen, België, 2009**

## Table of contents

List of abbreviations	xliii
Samenvatting	xxi
Summary	xxiv
Resumen	xxvii
<b>Chapter 1 – General Introduction</b>	<b>3</b>
1.1 Thesis overview	3
1.2 Thesis presentation	4
1.3 References	6
<b>Chapter 2 – The Human Immunodeficiency Virus</b>	<b>11</b>
2.1 Historical background	11
2.2 What is the origin of HIV	13
2.3 Viral characteristics, structure and genomic organization	14
2.4 Viral diversity	17
2.5 The HIV/AIDS epidemic	19
2.6 References	21
<b>Chapter 3 – The Infection by HIV</b>	<b>31</b>
3.1 Viral replication	31
3.2 Viral transmission across the mucosal barrier	33
3.3 Other mechanism of HIV transmission	36
3.4 The HIV infection and the mucosal innate immunity at the genital tract	37
3.4.1 Physical defence	38
3.4.2 Antimicrobial peptides	38
3.4.3 Cytokines and chemokines at the mucosal site	39
3.4.4 Effector cells at the genital mucosal	40
3.5 Viral pathogenesis: The HIV and the immune system	40
3.5.1 The early events of infection	40
3.5.2 The acute phase of HIV infection	41
3.5.3 The asymptomatic phase of infection	42
3.5.4 The symptomatic phase of infection	43
3.6 Therapy against HIV/AIDS	44
3.6.1 Antiviral compounds	45
3.6.2 Combination therapy: HAAT	48
3.7 Viral-resistance	50
3.7.1 Mechanism of antiretroviral drug resistance by drug class	50
3.7.2 Transmission of HIV resistant virus	53
3.7.3 HIV resistance in genital fluids	54
3.8 Prevention of HIV infection	54
3.8.1 The ABC strategy	55
3.8.2 Vaccines against HIV	55

3.8.3	Male circumcision	55
3.8.4	Prevention of HIV by chemoprophylaxis	56
3.8.5	Prevention of HSV	57
3.8.6	Microbicides	58
3.9	References	59

## **Chapter 4 – Microbicides for the Prevention of HIV-1** 81

4.1	The rationale for the development of microbicides	81
4.2	How could microbicides work?	82
4.2.1	Microbicides could act as a physical barrier	83
4.2.2	Microbicides could directly disrupt viral particles	83
4.2.3	Microbicides could promote the maintenance of vaginal environment and microflora	83
4.2.4	Microbicides could block viral attachment by blocking virus-cell charged interaction	84
4.2.5	Microbicides could block viral entry by blocking virus-cell interaction	84
4.2.6	Microbicides could block fusion of viral and cellular membranes	85
4.2.7	Microbicides could prevent infection by blocking reverse transcription of viral RNA to proviral DNA	85
4.2.8	Microbicides could prevent HIV infection by blocking glycan receptors	85
4.2.9	Microbicides could prevent HIV infection by preventing other STIs	86
4.3	Classes of microbicides	89
4.3.1	Microbicides based on their mechanism of action	89
4.3.2	Microbicides based on their site of application	90
4.4	Model systems for the preclinical research	91
4.4.1	Cell line based assays	91
4.4.2	Primary cell culture systems: PBMCs and Coculture of dendritic cells and CD4 <sup>+</sup> T cells	92
4.4.3	Tissue explants models	93
4.4.4	Small animal models	94
4.4.5	Non human primate models	95
4.5	Model systems for the research on preclinical safety of microbicides, the problem of lacking biomarkers?	96
4.6	Microbicides: from early expectations to current strategies	97
4.6.1	The earliest candidate microbicide	97
4.6.2	Candidate microbicides targeting direct HIV inactivation	98
4.6.3	Candidate microbicides targeting viral entry	99
4.6.4	Candidate microbicides targeting the HIV entry process	104
4.6.5	Candidate microbicides targeting the viral reverse transcription step	106
4.7	Delivery of microbicides products	111
4.8	References	113

3.8.3	Male circumcision	55
3.8.4	Prevention of HIV by chemoprophylaxis	56
3.8.5	Prevention of HSV	57
3.8.6	Microbicides	58
3.9	References	59

## **Chapter 4 – Microbicides for the Prevention of HIV-1** 81

4.1	The rationale for the development of microbicides	81
4.2	How could microbicides work?	82
4.2.1	Microbicides could act as a physical barrier	83
4.2.2	Microbicides could directly disrupt viral particles	83
4.2.3	Microbicides could promote the maintenance of vaginal environment and microflora	83
4.2.4	Microbicides could block viral attachment by blocking virus-cell charged interaction	84
4.2.5	Microbicides could block viral entry by blocking virus-cell interaction	84
4.2.6	Microbicides could block fusion of viral and cellular membranes	85
4.2.7	Microbicides could prevent infection by blocking reverse transcription of viral RNA to proviral DNA	85
4.2.8	Microbicides could prevent HIV infection by blocking glycan receptors	85
4.2.9	Microbicides could prevent HIV infection by preventing other STIs	86
4.3	Classes of microbicides	89
4.3.1	Microbicides based on their mechanism of action	89
4.3.2	Microbicides based on their site of application	90
4.4	Model systems for the preclinical research	91
4.4.1	Cell line based assays	91
4.4.2	Primary cell culture systems: PBMCs and Coculture of dendritic cells and CD4 <sup>+</sup> T cells	92
4.4.3	Tissue explants models	93
4.4.4	Small animal models	94
4.4.5	Non human primate models	95
4.5	Model systems for the research on preclinical safety of microbicides, the problem of lacking biomarkers?	96
4.6	Microbicides: from early expectations to current strategies	97
4.6.1	The earliest candidate microbicide	97
4.6.2	Candidate microbicides targeting direct HIV inactivation	98
4.6.3	Candidate microbicides targeting viral entry	99
4.6.4	Candidate microbicides targeting the HIV entry process	104
4.6.5	Candidate microbicides targeting the viral reverse transcription step	106
4.7	Delivery of microbicides products	111
4.8	References	113

<b>Chapter 5 – Project Outline</b>	139
5.1 Rationale	139
5.2 Aims of the study	140
5.3 Experimental strategy	142
5.4 References	150
<b>Chapter 6 – Targets for microbicides: are they effective?</b>	157
<b>In vitro Pre- and Post-Exposure Prophylaxis Using HIV Inhibitors as Microbicides against Cell-free or Cell-associated HIV-1 Infection</b>	
Abstract	158
6.1 Introduction	159
6.2 Materials and methods	160
6.3 Results	164
6.3.1 Entry and reverse transcriptase inhibitors exhibit efficient anti-HIV activity in a single-cycle infectious pseudovirus assay	164
6.3.2 In settings of pre-exposure prophylaxis, the antiviral activity of entry inhibitors is highly dependent on the viral input and viral source	165
6.3.3 In settings of post-exposure prophylaxis, only reverse transcriptase inhibitors can efficiently block both cell-free and cell-associated virus infection	169
6.3.4 Extended post-exposure prophylaxis efficacy of TMC120 against cell-free and cell-associated HIV infection of MO-DC/CD4 <sup>+</sup> T-cell cultures	171
6.3.5 Toxicity of entry and reverse transcriptase inhibitors in the MO-DC/CD4 <sup>+</sup> T cell co-cultures	171
6.4 Discussion	171
6.5 References	175
<b>Chapter 7 – Search for Novel Targets for Microbicides</b>	181
<b>HIV-1 Integration: A potential Target for Microbicides to Prevent Cell-free or Cell-associated Human Immunodeficiency Virus Type-1 Infection</b>	
Abstract	182
7.1 Introduction	183
7.2 Materials and methods	184
7.3 Results	189
7.3.1 Integrase inhibitors show potent antiviral activity in a single-cycle infectious pseudovirus assay	189

7.3.2	Integrase inhibitors completely block cell-free and cell-associated HIV-1 infection of primary target cells	190
7.3.3	Relative potency of integrase inhibitors, as compared to reference entry- and reverse transcriptase inhibitors against cell-free and cell-associated HIV-1 infection in primary cell cultures	191
7.3.4	Integrase inhibitors block infection with subtype C and CRF02_AG HIV-1 clinical isolates	195
7.3.5	The integrase inhibitor L-870812 and the reverse transcriptase inhibitor PMPA show a similar HIV blocking activity in an in vitro setting of post-exposure prophylaxis	196
7.3.6	The integrase inhibitor L-870812 shows synergistic activity in combination with a fusion or reverse transcriptase inhibitors	197
7.3.7	The entry- reverse transcriptase- and integrase inhibitors show limited or delayed toxic effects towards dendritic cells and CD4 <sup>+</sup> T cells co-cultures	198
7.4	Discussion	199
7.5	References	203

## **Chapter 8 – Resistance selection: Can we avoid it?** 211

### **Spectrum of Induced Resistance towards the Candidate Microbicide Dapivirine in various HIV-1 subtypes: A Critical Evaluation of the Potential Consequences**

Abstract		212
8.1	Introduction	213
8.2	Materials and methods	215
8.3	Results	218
8.3.1	Selection of subtype B, C and CRF-02 HIV-1 strains resistant to the reverse transcriptase inhibitors Dapivirine and Nevirapine	218
8.3.2	Reverse transcriptase inhibitors from first- or second-line therapy are differentially active against NNRTI microbicide resistant viruses	221
8.3.3	TMC120-resistant virus is cross-resistant to new-generation NNRTI, but not to fusion or integrase inhibitor	222
8.3.4	Could RTI candidate microbicides block NNRTI-resistant viruses?	223
8.3.5	Evaluation of toxic effects	225
8.4	Discussion	225
8.5	References	229

<b>Chapter 9 – General discussion, Conclusions and Perspectives</b>	237
9.1 Prevention of HIV-1 transmission by a women-controlled method	237
9.2 The experimental model and the search for potential candidate Microbicides	238
9.3 Search for efficient targets for microbicides	239
9.4 A new potential target for blocking HIV-1 transmission	240
9.5 HIV-1 resistance associated to microbicides and the potential consequences	241
9.6 Challenges/caveats in the research of HIV-1 microbicides, why do we fail?	242
9.7 General conclusion	244
9.8 Perspectives	244
9.9 References	247
<b>Acknowledgements</b>	255